1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E50BB57E147C4E5900258ABE003AAA3E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-oncology-field-medical-excellence-europe-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2044.210.149.205
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Oncology Field Medical Excellence in Europe: Establishing Standards for High Performance & Impact

ID: 5792


Features:

9 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 28


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Oncology Field Medical Excellence in Europe: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The oncology market in Europe is a dynamic and rapidly evolving sector, characterized by its diverse healthcare systems, regulatory frameworks, and nuanced market dynamics spanning multiple countries. Within this intricate landscape, optimizing the efficiency of field medical teams emerges as a strategic imperative for oncology manufacturers aiming to establish a strong foothold in the region.

Best Practices, LLC undertook this benchmarking research to empower Oncology Field Medical Excellence leaders in crafting a framework that fosters consistency and maximizes impact in Europe. The study delivers strategic insights tailored to enhance KOL interactions, assess MSL performance, and strategically align staffing footprints.

KEY TOPICS

  • Effective Oncology Field Performance Metrics in Europe
  • Building an Oncology Field Medical Excellence Framework
  • Target and Engagement Levels of Oncology KOLs in Europe
  • Average Time Oncology MSLs Spend on KOL Interactions and Internal Activities in Europe
  • Oncology Field Medical Staffing Footprint in Europe
  • Key Insights and Lessons Learned for Measuring the Impact of Oncology MSLs in Europe

KEY METRICS

  • Europe field scorecard: Benchmarking oncology engagements
  • Average number of tiered vs. non-tiered KOLs per Oncology MSL in Europe
  • Monthly KOL and F2F interactions in Europe – Oncology segment
  • Weighting criteria for various interaction types on the Oncology MSL scorecard (Europe)
  • Metrics for engaging non-tiered Oncology KOLs in Europe
  • Average Oncology MSL time in the field (days per year) in Europe
  • Percentage of Oncology MSL time spent on external, internal, and logistics activities in Europe
  • Weekly Oncology MSL time allocation for each activity stream in Europe
  • Percentage of overall oncology targets classified as KOLs, HCPs, payers, or other external stakeholders in Europe
  • Oncology field medical staffing footprint in Europe

SAMPLE KEY FINDINGS

  • Metrics for Engaging Non-Tiered Oncology KOLs in EU: Special metrics for engaging non-tiered KOLs are not common for EU Oncology teams, with only 20% using it. This trend resonates beyond oncology, as a mere 9% of teams across all therapeutic areas in the EU deploy specialized metrics to gauge the engagement of non-tiered KOLs.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from oncology companies around the world through a custom benchmark survey. Focused on oncology field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.